Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 9/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 6/20 | 0.34 |
| ▸ | HTR2C | P28335 | 6/20 | 0.34 |
| ▸ | HTR2B | P41595 | 5/20 | 0.34 |
| ▸ | HTR6 | P50406 | 2/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19711557 | 0.82 | PNMT (0.39) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL19684796 | 0.79 | PNMT (0.49) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL19710976 | 0.79 | PNMT (0.37) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL23735162 | 0.79 | PNMT (0.37) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL23897085 | 0.77 | PRMT5 (0.36) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL23735224 | 0.77 | HTR2C (0.35) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL19710968 | 0.77 | PNMT (0.35) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL19684794 | 0.76 | PNMT (0.45) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL19710964 | 0.76 | HTR2A (0.41) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL19710973 | 0.76 | PNMT (0.34) | PNMTHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464249-B1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2021-08-11 | — | — | EP | disclosed |
| WO-2017213825-A1 | TREATMENT METHODS HAVING REDUCED DRUG-RELATED TOXICITY AND METHODS OF IDENTIFYING THE LIKELIHOOD OF PATIENT HARM FROM PRESCRIBED MEDICATIONS | TABULA RASA HEALTHCARE, INC. (US) | 2017-12-14 | — | — | WO | disclosed |